Will attend #Sachs_BEF Basel Sept 21-22 2022 

Our Company

BiPER Therapeutics is a preclinical-stage biotech company founded in 2021 to develop and commercialize novel therapeutics. We are developing a first-in-class pipeline of small molecules targeting the global metabolism of cancer. BiPER 's name summarizes the original and unique approach of our first portfolio of therapeutics : Our drug candidates target BiP, an key protein involved in cancer cells survival and associated with poor prognosis of patients, triggering cancer cell death and tumour growth inhibition through ER (Endoplasmic Reticulum) Stress induction.

New Therapeutic Solutions 

False colour transmission electron microscope micrograph showing a continuity between the

Resistance to standard chemotherapeutic treatments and poor responses to immune-based therapies represent major challenges in cancer treatment as many patients respond poorly or not at all to currently available treatment options.

BiPER Therapeutics aims to bridge this important treatment gap by developing novel therapeutic solutions based on these core principles: 

 

  • Targeting the global metabolism of cancer cells
     

  • Modulating the Endoplasmic Reticulum Stress (ER stress) a pathway involved in cancer treatment resistance
     

  • Developing BPR series of First-In-Class small molecules selectively targeting BiP/GRP78 a key chaperone protein involved in ER stress
     

  • Selectively activating cell death in cancer cells to treat resistant as well as sensitive cancers
     

Founders & Executive Team

Photo Pro_Mehdi_CHELBI Mehdi_2018-08-06.jpg

Mehdi Chelbi

MSc


Co-Founder & CEO

  • Grey LinkedIn Icon

Biotech - Pharma - CRO
Corporate & Drug Development Experience 

Photo Stephane HQ.JPG

Stephane Rocchi

PhD - Research Director Inserm


Co-Founder 

 

  • Grey LinkedIn Icon

Expertise in Biology and Translational Research in Oncology @ C3M

Photo Rachid HQ.jpg

Rachid Benhida

PhD - Research Director CNRS

Co-Founder 

 

  • Grey LinkedIn Icon

Expertise in Medicinal Chemistry, Drug Design and Pharmacology @ICN

Photo Cyril HQ.jpg

Cyril Ronco

PhD - MC - HDR


Co-Founder 

 

  • Grey LinkedIn Icon

Expertise in Medicinal Chemistry, Drug Design and Pharmacology @ICN

Pipeline

Pipeline BiPER TX_2021-10-12.png

Ecosystem & Partners

BPI logo.png
Inserm Transfert Logo.png
Region Grand Est.png
Logo Semia.png
MATWIN Logo.png
C3M Logo.jfif
ICN Logo.png
Logo Canceropôle_PACA_DEF.jpg
BioValley.png
BiPER Logo on Blue.png

11 Rue de l'Académie

67000 Strasbourg

France

 

contact@biper-tx.com